Stock listing
TPEx:6620 Handa Pharmaceuticals Inc (漢達) 股價
Follow Handa Pharmaceuticals Inc into a list and get an email when it puts out news.
Share price · TPEX:6620
$82.30 TWD -19.20 (-18.9%)
Close on Nov 20, 2026
- Day range
- $82.30 – $89.90 TWDNov 20, 2026
- Volume
- 2.33M sharesNov 20, 2026
- Market cap
- $13.38B TWDAt the close on Nov 20, 2026 · price × 162.5M shares outstanding
- 52-week range
- $64.10 – $155.00 TWDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $393.5M TWDMedian day 2.77M shares · 1 day with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · TPEX:6620 · TWD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $82.30 | -19.20 | -18.9% | $89.90 | $89.90 | $82.30 | 2,334,440 | |
| $101.50 | -7.00 | -6.5% | $108.50 | $108.50 | $100.50 | 2,127,486 | |
| $108.50 | +1.00 | +0.9% | $103.00 | $110.50 | $102.00 | 2,598,322 | |
| $107.50 | -11.50 | -9.7% | $117.00 | $117.50 | $107.50 | 2,496,931 | |
| $119.00 | -4.00 | -3.3% | $118.50 | $125.50 | $114.50 | 3,263,279 | |
| $123.00 | -13.50 | -9.9% | $130.00 | $132.00 | $123.00 | 3,303,200 | |
| $136.50 | +11.00 | +8.8% | $132.00 | $137.50 | $126.50 | 4,981,851 | |
| $125.50 | +11.00 | +9.6% | $118.50 | $125.50 | $118.50 | 5,442,498 | |
| $114.50 | +10.00 | +9.6% | $104.50 | $114.50 | $102.00 | 2,380,627 | |
| $104.50 | +4.00 | +4.0% | $90.50 | $110.50 | $90.50 | 6,195,882 | |
| $100.50 | -11.00 | -9.9% | $100.50 | $100.50 | $100.50 | 1,785,881 | |
| $111.50 | -12.00 | -9.7% | $125.00 | $127.00 | $111.50 | 3,882,677 | |
| $123.50 | -3.00 | -2.4% | $125.00 | $129.00 | $118.00 | 2,377,099 | |
| $126.50 | -6.00 | -4.5% | $128.00 | $130.00 | $123.50 | 1,462,946 | |
| $132.50 | -5.00 | -3.6% | $135.50 | $137.50 | $130.00 | 1,663,895 | |
| $137.50 | +1.00 | +0.7% | $136.50 | $140.50 | $134.00 | 1,435,860 | |
| $136.50 | +2.00 | +1.5% | $135.50 | $140.50 | $133.50 | 1,501,883 | |
| $134.50 | -4.50 | -3.2% | $140.00 | $146.00 | $134.50 | 2,858,164 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | +5.50 | +4.1% | $134.50 | $146.00 | $133.50 | 3,807,373 | |
| $133.50 | +4.00 | +3.1% | $132.50 | $133.50 | $129.50 | 1,537,807 | |
| $129.50 | -8.50 | -6.2% | $140.50 | $143.50 | $129.50 | 2,930,126 | |
| $138.00 | -5.50 | -3.8% | $142.00 | $145.00 | $135.00 | 3,727,297 | |
| $143.50 | +13.00 | +10.0% | $133.50 | $143.50 | $133.50 | 5,336,202 | |
| $130.50 | -6.00 | -4.4% | $134.00 | $141.00 | $130.50 | 5,678,888 | |
| $136.50 | +12.00 | +9.6% | $127.50 | $136.50 | $127.50 | 2,385,522 | |
| $124.50 | -3.00 | -2.4% | $126.00 | $129.50 | $124.00 | 1,114,825 | |
| $127.50 | 0.00 | 0.0% | $124.00 | $130.00 | $124.00 | 841,362 | |
| $127.50 | +2.50 | +2.0% | $126.50 | $133.00 | $126.00 | 2,099,200 | |
| $125.00 | -8.00 | -6.0% | $130.50 | $132.50 | $124.00 | 2,992,492 | |
| $133.00 | -13.00 | -8.9% | $145.00 | $145.00 | $131.50 | 4,537,465 | |
| $146.00 | +2.50 | +1.7% | $146.00 | $150.00 | $143.00 | 4,123,835 | |
| $143.50 | -1.00 | -0.7% | $145.00 | $149.50 | $142.50 | 3,957,518 | |
| $144.50 | +3.50 | +2.5% | $145.50 | $154.50 | $140.50 | 9,018,110 | |
| $141.00 | +5.00 | +3.7% | $137.50 | $145.00 | $133.00 | 7,315,077 | |
| $136.00 | +12.00 | +9.7% | $125.00 | $136.00 | $123.50 | 2,916,112 | |
| $124.00 | -6.00 | -4.6% | $129.00 | $129.00 | $120.00 | 2,688,101 | |
| $130.00 | +3.50 | +2.8% | $126.50 | $132.50 | $125.00 | 2,847,275 | |
| $126.50 | -11.00 | -8.0% | $137.50 | $137.50 | $125.00 | 5,203,047 | |
| $137.50 | -11.50 | -7.7% | $151.50 | $152.00 | $135.00 | 6,128,968 | |
| $149.00 | +2.00 | +1.4% | $147.00 | $155.00 | $140.50 | 9,852,017 | |
| $147.00 | +13.00 | +9.7% | $143.00 | $147.00 | $143.00 | 2,014,935 | |
| $134.00 | +12.00 | +9.8% | $119.00 | $134.00 | $118.50 | 2,935,011 | |
| $122.00 | -5.00 | -3.9% | $127.50 | $132.50 | $122.00 | 2,030,611 | |
| $127.00 | +3.00 | +2.4% | $125.00 | $128.00 | $120.00 | 1,385,166 | |
| $124.00 | -2.50 | -2.0% | $123.50 | $126.50 | $123.50 | 1,337,737 | |
| $126.50 | -5.50 | -4.2% | $128.50 | $129.00 | $124.00 | 2,141,043 | |
| $132.00 | +8.00 | +6.5% | $127.50 | $132.00 | $127.00 | 2,905,054 | |
| $124.00 | +11.00 | +9.7% | $121.50 | $124.00 | $120.00 | 5,893,086 | |
| $113.00 | +5.50 | +5.1% | $114.50 | $118.00 | $107.50 | 9,322,211 | |
| $107.50 | +9.50 | +9.7% | $105.00 | $107.50 | $97.10 | 6,781,602 | |
| $98.00 | +2.60 | +2.7% | $92.90 | $103.50 | $92.00 | 3,552,146 | |
| $95.40 | +8.60 | +9.9% | $87.90 | $95.40 | $87.70 | 2,889,000 | |
| $86.80 | -6.10 | -6.6% | $102.00 | $102.00 | $86.80 | 4,698,055 | |
| $92.90 | +8.40 | +9.9% | $92.90 | $92.90 | $92.90 | 650,000 | |
| $84.50 | +7.60 | +9.9% | $77.10 | $84.50 | $77.10 | 1,189,150 | |
| $76.90 | +1.10 | +1.5% | $75.80 | $78.20 | $75.80 | 264,000 | |
| $75.80 | +1.20 | +1.6% | $74.60 | $77.10 | $74.60 | 188,002 | |
| $74.60 | -1.20 | -1.6% | $75.80 | $75.80 | $74.10 | 297,100 | |
| $75.80 | +0.80 | +1.1% | $75.00 | $76.00 | $74.70 | 159,002 | |
| $75.00 | -0.80 | -1.1% | $75.50 | $76.60 | $75.00 | 212,000 | |
| $75.80 | +1.00 | +1.3% | $74.80 | $76.70 | $74.80 | 184,000 |
- Ticker
- TPEx:6620
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- TPEx
- Currency
- TWD
Handa Pharmaceuticals Inc on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
Valuation
P/E 27.3× against a median of 35.7×: 4th lowest of 8 Pharmaceuticals companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $9.65B TWD
- P/E
- 27.3×
- EV/sales
- 8.0×
- EV/EBITDA
- 15.6×
- Price/book
- 2.7×
- Gross margin
- 81.4%
- Operating margin
- 37.5%
- Net margin
- 40.5%
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Handa Pharmaceuticals Inc · TPEX:6620 | US$405.8M | US$292.6M | 27.3× | 8.0× | 15.6× | 2.7× | 40.5% | 0.0× | n/a |
| Zhejiang Chengyi Pharmaceutical Co. Ltd. Class A · SSE:603811 | US$426.4M | US$399.3M | 15.0× | 3.2× | n/a | 1.9× | 22.8% | 0.0× | n/a |
| Harbin Medisan Pharmaceutical Co., Ltd. Class A · SZSE:002900 | US$413.1M | US$377.4M | n/a | 3.0× | n/a | 1.6× | −27.1% | 0.1× | n/a |
| PKU Healthcare Corp. Ltd. Class A · SZSE:000788 | US$412.4M | US$243.9M | 133× | 1.8× | n/a | 1.8× | 2.3% | 0.0× | n/a |
| CorMedix Inc. · NASDAQ:CRMD | US$410.8M | US$201.0M | 6.4× | 0.5× | 1.0× | 0.9× | 15.5% | 0.3× | 0.71 |
| Huaren Pharmaceutical Co., Ltd. Class A · SZSE:300110 | US$409.9M | US$445.4M | n/a | 2.4× | n/a | 3.2× | −40.2% | 0.5× | n/a |
| ScinoPharm Taiwan, Ltd. · TWSE:1789 | US$404.2M | US$324.5M | 797× | 3.5× | n/a | 1.3× | 0.5% | 0.1× | n/a |
| Zhuhai Rundu Pharmaceutical Co. Ltd. Class A · SZSE:002923 | US$401.6M | US$381.7M | 47.1× | 1.9× | n/a | 2.4× | 4.2% | 0.2× | n/a |
| Cheng Du Sheng Nuo Biotec Co., Ltd. Class A · SSE:688117 | US$398.5M | US$406.8M | 12.7× | 2.8× | n/a | 2.3× | 21.8% | 0.3× | n/a |
| Kexing Biopharm Co., Ltd. Class A · SSE:688136 | US$398.1M | US$410.5M | 35.7× | 2.1× | n/a | 1.5× | 5.7% | 0.4× | n/a |
| Shaanxi Kanghui Pharmaceutical Co. , Ltd. Class A · SSE:603139 | US$393.1M | US$396.8M | n/a | 5.1× | n/a | 3.9× | −38.4% | 0.2× | n/a |
| Median of the others | US$407.1M | US$389.3M | 35.7× | 2.6× | 1.0× | 1.9× | 3.2% | 0.2× | 0.71 |
Forecasts
Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 83.00 TWD · Analysts' mean
- EPS, year to Dec 2027
- 5.11 · 1 analyst
Team and board
| Officer | Role |
|---|---|
| Bill Liu | President and Chief Executive Officer |
| Li Qiao | SVP Program Management & Regulatory Affairs & COO |
| David Quiggle | Vice President – Regulatory Affairs |
| George Kraft | Vice President – Corporate Development |
| Maggie Chang | Executive Vice President – Quality Affairs |
| Michael He | Vice President – Product Development |
| Alex Huang | Director – Corporate Development |
Events
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Sep 30, 2026 | Nov 15, 2026 · Before open | −9.7% |
| Q2 2026 | Aug 14, 2026 | −4.5% |
Financials
Annual, in TWD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1.73B | 830.7M | 1.11B | 197.7M | 29.2M |
| Cost of revenue | 267.5M | 1.17M | 1.30M | 18.7M | 1.46M |
| Gross profit | 1.46B | 829.5M | 1.11B | 179.0M | 27.8M |
| Research and development | 362.6M | 291.9M | 267.3M | 179.8M | 209.0M |
| Selling, general and administrative | 165.0M | 119.5M | 144.3M | 87.3M | 72.7M |
| Operating income | 934.2M | 418.1M | 693.4M | -88.1M | -253.9M |
| Depreciation and amortization | 164.1M | 10.4M | 12.4M | 15.2M | 35.2M |
| EBITDA | 1.10B | 428.5M | 705.9M | -72.9M | -218.7M |
| Interest expense | 2.20M | 492.0K | 222.0K | 281.0K | 232.0K |
| Income before tax | 937.0M | 479.2M | 792.5M | -43.1M | -260.8M |
| Net income | 749.8M | 472.7M | 726.9M | -40.0M | -247.7M |
| Earnings per share, basic | 4.45 | 3.37 | 5.15 | -0.30 | -1.98 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash and equivalents | 1.81B | 597.4M | 667.0M | 365.9M | 263.3M |
| Short-term investments | 1.90B | 1.23B | 1.65B | 2.59M | 33.3M |
| Receivables | 580.0M | 190.4M | 376.4M | 153.5M | 7.79M |
| Inventory | 0 | 41.2M | 0 | ||
| Current assets | 4.31B | 2.11B | 2.71B | 592.9M | 314.3M |
| Goodwill | 35.9M | 35.9M | 34.9M | 34.9M | 34.9M |
| Total assets | 5.89B | 3.44B | 3.04B | 790.6M | 498.5M |
| Accounts payable | 30.2M | 20.8M | 14.0M | 6.22M | 1.08M |
| Current liabilities | 117.8M | 241.4M | 209.5M | 45.4M | 29.7M |
| Total liabilities | 232.1M | 324.1M | 280.9M | 69.4M | 35.4M |
| Shareholders' equity | 5.66B | 3.12B | 2.76B | 721.1M | 463.1M |
| Shares outstanding | 168.5M | 140.5M | 141.1M | 132.2M | 125.0M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash from operations | 243.6M | 497.6M | 668.4M | -211.6M | -179.2M |
| Capital spending | -17.1M | -7.77M | -944.0K | -758.0K | -7.15M |
| Free cash flow | 226.5M | 489.8M | 667.4M | -212.3M | -186.4M |
| Dividends paid | -236.3M | -141.1M | |||
| Share buybacks | -57.9M | -56.5M | 0 | ||
| Change in cash | 1.21B | -69.7M | 301.1M | 102.6M | -16.8M |
Cap table
Built by 6ix from Handa Pharmaceuticals Inc’s releases
- Common shares
- 162,530,100
- Fully diluted
- 162,530,100
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 162,530,100 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 162,530,100 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Alex Huang | Director – Corporate Development · Since at least Nov 5, 2026 |
| Bill Liu | President and Chief Executive Officer · Since at least Nov 5, 2026 |
| David Quiggle | Vice President – Regulatory Affairs · Since at least Nov 5, 2026 |
| George Kraft | Vice President – Corporate Development · Since at least Nov 5, 2026 |
| Li Qiao | SVP Program Management & Regulatory Affairs & COO · Since at least Nov 5, 2026 |
| Maggie Chang | Executive Vice President – Quality Affairs · Since at least Nov 5, 2026 |
| Michael He | Vice President – Product Development · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Handa Pharmaceuticals Inc.